Table 2

Cox multivariate regression analysis of factors predicting continuous RA-related WD in patients with a recent diagnosis of RA

HR (95% CI)p Value
Age1.08 (1.07 to 1.09)<0.001
Male1.50 (1.31 to 1.72)<0.001
RF present1.12 (0.97 to 1.30)0.11
Year cohort<0.001*
 2000–11 (reference)
 2002–30.79 (0.67 to 0.93)
 2004–50.51 (0.42 to 0.61)
 2006–70.35 (0.27 to 0.44)
Medication (first 3 months)<0.001
 Single other1 (reference)
 Single MTX1.33 (1.05 to 1.69)
 Combination other1.28 (1.02 to 1.62)
 Combination including MTX1.52 (1.29 to 1.79)
 None1.17 (0.89 to 1.54)
Adalimumab or etanercept initiated at any time while available to work0.61 (0.39 to 0.97)0.036
Number of WD days in year before index day corresponding to 1 month's change1.12 (1.06 to 1.18)<0.001
  • * p for linearity.

  • MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; WD, work disability.